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Introduction
Idiopathic thrombocytopenic purpura (ITP) is an auto-
immune disorder. Platelet antibody IgG is increased in
acute and chronic ITP patients. In children, it is most
often an acute disorder, and platelet antibody IgM is
significantly higher in acute ITP.1 In adults, it is most
often a chronic condition persisting for more than 
6 months.
Platelet refractoriness is caused by human leuko-
cyte antigen (HLA) antibodies and platelet-specific
antibodies.2–6 The characteristic of decreased recovery
and survival of transfused platelets in nonalloimmu-
nized patients with ITP suggests that platelet-specific
antibodies and/or HLA autoantibodies are present in
the plasma of almost all cases. In patients with ITP,
platelet-specific antibodies that recognize platelet gly-
coproteins were reported more frequently.7–10
A number of methods have been developed for the
detection of platelet-specific antibodies and HLA anti-
bodies, such as solid phase red cell adherence (SPRCA)
assay,11,12 platelet immunofluorescence assay,13 and
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antigen-capture assays such as the monoclonal anti-
body-specific immobilization of platelet antigen assay.14
The speed and simplicity of the SPRCA method allow
many hospital laboratories to use the SPRCA assay for
platelet antibody screening and crossmatching. Draw-
backs of these tests are their insensitivity.
Flow cytometry is a sensitive method for the detec-
tion of platelet antibodies.15–17 Many platelet antibody
tests have been evaluated in the diagnosis of ITP due to
its immune nature.18 Several publications have described
flow cytometric methods for the detection of platelet
antibodies in patients with ITP.19,20
In this study, we used 2 indirect methods to detect
HLA antibodies and/or platelet-specific antibodies in
sera and 1 direct method to detect IgG antibodies on
platelets obtained from adult patients with ITP. We
evaluated whether or not flow cytometric assays using
normal platelets as targets are more informative for
the evaluation of ITP.
Methods
Patients and controls
A total of 44 adult patients were clinically classified as
having ITP using the following criteria: true throm-
bocytopenia (reviewed by blood smear); bone marrow
aspiration with an increased or normal percentage of
megakaryocytes; no other evident clinical cause of the
thrombocytopenia other than an immune mechanism.16
Sera from another 10 patients (6 female, 4 male;
median age, 57 years; age range, 17–83 years) with
non-immune thrombocytopenia (aplastic anemia, 2;
paroxysmal nocturnal hemoglobinuria, 1; myelodys-
plastic syndrome, 2; hepatitis, 1; disseminated intravas-
cular coagulation, 1; multiple myeloma, 1; lymphoma,
1; familial thrombocytopenia, 1) were also studied.
The negative serum control was from 1 of the
normal blood donors (25 male; median age, 23 years;
age range, 19–26 years) who had never received a trans-
fusion. A pool of 5 highly sensitized patient sera was
used as positive control.
Indirect methods
We used 2 indirect methods (method I, SPRCA assay;
method II, flow cytometry using donor platelets as
target cells) to detect HLA and/or platelet-specific
antibodies in the sera.
Method I: SPRCA test
We used the SPRCA test (Capture-P Solid Phase
System; Immucor, Norcross, GA, USA). We employed
the platelets from 7 donors as the target cells. The
platelets from each donor’s apheresis platelets were lay-
ered in different wells, and the patient’s serum and neg-
ative and positive control sera were added in individual
wells. The wells were washed and anti-IgG-coated indi-
cator red cells added. If antibodies to the platelets are
present, the indicator red cells would form a thin film
in the well; but if no platelet antibodies are present, the
indicator red cells would pellet to the bottom of the
well, forming a red button.
Method II: flow cytometry using donor platelets as
target cells
Platelet preparation: We utilized platelets from 10 fresh
plateletpheresis components as target cells to screen
platelet antibodies (HLA antibodies and/or platelet-
specific antibodies) in the sera. The platelets were
washed twice with a mixture of phosphate-buffered
saline (PBS) and anticoagulant citrate dextrose solution
(ACD) formula A (Baxter Healthcare Co., Fenwal
Division, Deerfield, IL, USA) (PBS/ACD = 9/1) with
the pH adjusted to 7.0, by centrifugation at 1,400g for
5 minutes. Washed platelets were pooled. We adjusted
the platelet count to 200 × 106/L with PBS/ACD.
The reagent platelets were prepared on the day of analy-
sis and were not stored for future use.
Antibody test: Equal volumes (50μL) of patients’ sera
and pooled platelets were incubated at 37°C for 30 min-
utes, respectively. The cells were then washed twice with
PBS/ACD mixture at 1,400g for 5 minutes. The sensi-
tized platelets were resuspended in 100 μL PBS/ACD
and incubated for 30 minutes in the dark at room tem-
perature with 10μL fluorescein isothiocyanate (FITC)-
conjugated sheep anti-human IgG Fc (The Binding Site
Ltd., Birmingham, UK). They were then washed twice
in PBS/ACD. We resuspended the pellet in 200 μL
PBS/ACD by shaking the tubes on a vortex for 15 sec-
onds and promptly analyzed them on a flow cytometer
(Epics XL; Coulter Electronics, Hialeah, FL, USA).
We analyzed approximately 5,000 platelets per test.
A negative reference range was determined by using
sera from never-transfused males. We set the analysis
region with the negative reference range in the FL1
histogram. Positive results were defined as any test with
the percentage of fluorescence exceeding the reference
range by 3% or more.21 Negative and positive control
sera were included in each test.
Direct method using flow cytometry
For detecting platelet-associated IgG (PAIgG) on 
the platelet surface, platelets from patients with ITP
were washed twice. The platelets were incubated with
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FITC-conjugated sheep anti-human IgG Fc. They were
then washed twice and analyzed on the flow cytometer.
The negative platelet control was from normal males
who had never received a transfusion. The platelets
that were sensitized with a pool of 5 highly sensitized
patients’ sera were used as positive control. We ana-
lyzed approximately 5,000 platelets per test. Positive
results were defined as any test with the percentage of
fluorescence exceeding the negative control by 3% or
more.22
Statistical analysis
Statistical analysis of the data was performed using SPSS
version 12.0 (SPSS Inc., Chicago, IL, USA). The
platelet counts of patients with positive and negative
tests were compared using the Mann–Whitney test.
The difference between the results of SPRCA and
method II was compared by the McNemar test. The
level of agreement of the results of SPRCA assay and
method II was assessed by the κ coefficient. The figure
of distribution of percent fluorescence was done using
SigmaPlot 8.02 (Systat Software, Point Richmond, CA,
USA). A p value<0.05 was considered to be significant.
Results
A total of 44 patients with ITP (28 female, 16 male)
were studied. The median age of the patients with ITP
was 53 years (range, 23–90 years). The median interval
between initial onset of thrombocytopenia and blood
sampling for platelet antibody testing was 35 days
(range, 0–2,555 days), and 21 sera were sampled within
7 days.
Patients’ sera were tested for platelet antibodies by
methods I and II. The test results are presented in
Table 1. The results of the SPRCA assay and method II
were in moderate agreement (κ coefficient=0.555). All
assays yielded negative results for negative control sera.
The SPRCA assay could only detect platelet anti-
bodies in 22 patients (50%). The mean platelet counts
of patients with positive (40.0±32.7×109/L) and neg-
ative (41.7 ± 40.4 × 109/L) SPRCA tests did not differ
significantly (p = 0.90).
Using method II, 31 serum specimens (70.5%)
yielded positive results. There was a difference between
the results of SPRCA testing and method II, with a
high degree of significance (p < 0.001) according to the
McNemar test.
Using method II, the mean percentage of fluores-
cence of negative serum control and non-immune
thrombocytopenia were 3.03±1.68% and 2.45±0.95%,
respectively, and they were similar (p = 0.33). The mean
percentage of fluorescence in ITP patients was 12.01 ±
12.01%, which was significantly higher than those of the
negative control (p < 0.001) and non-immune throm-
bocytopenia (p < 0.001) (Figure 1).
Of the 10 patients with non-immune thrombocy-
topenia, neither of these 2 different assays for platelet
antibodies had any positive results.
The platelets obtained from 19 patients with ITP
were available for direct testing. Twelve (66.7%) of
these 18 specimens produced positive results.
Discussion
Circulating platelet autoantibodies are involved in the
pathogenesis of ITP.7–10 The primary mechanism of
thrombocytopenia in ITP is that platelets opsonized
by platelet autoantibodies are destroyed by the reticu-
loendothelial system. Activation of complements on
the platelet surface may occur in some patients with
ITP. Tsubakio et al demonstrated that ITP autoanti-
bodies, anti-HLA and platelet-specific antibodies (e.g.
anti-HPA-1a) activate the complement pathway to a
similar degree, and platelet lysis by autoantibodies and
complement may occur in some chronic ITP patients.23
McMillan et al found that autoantibodies in plasma
obtained from some adult patients with ITP inhibit 
in vitro megakaryocyte production, suggesting that a
similar effect may occur in vivo.24
Some patients with ITP were associated with auto-
immune disorders such as autoimmune hemolytic ane-
mia and idiopathic neutropenia.25,26 The autoantibodies
are directed against antigens specific for the various
peripheral blood cells, i.e. platelets, erythrocytes, and
granulocytes, and they are not cross-reactive. Polyclonal
autoantibodies suggested generalized immune dys-
regulation in patients with multiple autoimmune
manifestations.27
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Table 1. Results of solid phase red cell adherence (SPRCA)
assay (method I) and flow cytometric assay* (method II) in 
44 patients with idiopathic thrombocytopenic purpura
SPRCA Flow cytometric analysis Patients





*Using donor platelets as target cells.
Both the SPRCA test and flow cytometric assay
that use platelets as the target cells will detect platelet-
specific antibodies and antibodies to HLA class I anti-
gens. These tests will detect both alloantibodies and
autoantibodies, but will not distinguish between them.
The SPRCA test is a common laboratory test to evalu-
ate the presence of platelet antibodies. The interpreta-
tion of the SPRCA test is straightforward, and the kit
provides good control material to ensure that the
results are valid. But it has been reported that antibodies
are not always detected with this assay. Jones et al
reported that the SPRCA method showed 65% sensi-
tivity and 100% specificity for detecting PAIgG in
ITP.28 Raife et al reported that the sensitivity of the
SPRCA test for the clinical diagnosis of ITP was 43%
for the indirect method.29 In our study, the SPRCA
method showed 50% sensitivity and 100% specificity for
detecting plasma antiplatelet antibodies.
Flow cytometry is sensitive, but it lacks the ability to
differentiate between pathologic and non-pathologic
PAIgG. Many patients with non-immune thrombocy-
topenia also have high PAIgG.30 Thrombocytopenia
in some patients with septicemia may be related to the
binding of IgG to platelets.31 Total PAIgG measure-
ments in thrombocytopenic patients may reflect platelet
size, which is known to be increased in response to
thrombopoietic stress.32 One exception to this interpre-
tation is that increased total PAIgG content merely
reflects their increased plasma IgG in patients who have
disorders with increased plasma IgG concentrations.33
Latorraca et al studied 14 patients with chronic ITP
using flow cytometry; the direct test (anti-platelet
antibodies on the platelet surface) was positive in 7
patients (50%), and the indirect test (detecting platelet
antibodies in sera) was positive in 8 patients (57%).19
In our study, the direct test was positive in 66.7% of
patients tested, while the indirect test using method II
was positive in a higher number of patients (70.5%).
Although the clinical diagnosis of ITP is generally
satisfactory in “typical” cases, demonstration of platelet
autoantibodies supports an immune-mediated patho-
logic process in patients with ITP. Sensitive methods for
platelet antibodies are not readily adaptable to routine
clinical laboratories. In this study, the 70.5% sensitivity
by flow cytometry is still not very sensitive. The diag-
nosis of ITP needs both clinical evidence and laboratory
data to exclude other causes of thrombocytopenia.
According to the guidelines of the American Society
of Hematology, no serologic tests are necessary to
diagnose clear ITP.21
Possible factors influencing the detection rate may
include the following: the selection of patients in differ-
ent stages of disease; presence of both alloantibodies and
autoantibodies in some patients with ITP; the method-
ologic difference in flow cytometry; the use of fresh
donor platelets to decrease background fluorescence;
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Figure 1. Box plot for percent fluorescence by method II in 25 normal controls, 44 idiopathic thrombocytopenic purpura (ITP) patients
and 10 non-immune thrombocytopenia patients. The box represents the interquartile range, and the line within the box represents the
median. The bar represents the standard deviation. The open circles are outliers.
and the number of donors from whom the target
platelets were obtained. In this study, a pooled platelet
suspension from 10 donors was used for flow cytome-
try; nevertheless, in the SPRCA assay, platelets from 
7 single donors were used as target cells. The target
platelets used in flow cytometry and the SPRCA assay
were obtained from different donors, because these 
2 tests were performed on different dates and fresh
platelets were chosen as targets.
We conclude that flow cytometry assay using donor
platelets as target cells allows detection of autoantibod-
ies in 70% of patients with ITP. Flow cytometry is more
sensitive than SPRCA assay for detecting platelet anti-
bodies. Definite proof regarding the presence of platelet
antibodies is useful in explaining the immune mecha-
nism and platelet transfusion refractoriness.
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